Skip to content
Search

Latest Stories

JOINT CARE: Supplements support joint health

Joint Care : Dr Rod Hughes sets out how pharmacists can play a pivotal role in steering people with joint pain towards a prevention programme…

Joint health supplements are big business in the UK, with millions of pounds spent over the counter every year. People turn to these supplements for various reasons, but most are seeking relief from the symptoms of arthritis, a group of painful long-term conditions thought to affect around 10 million people in this country.


Osteoarthritis (OA) is the most common form of arthritis, affecting around eight million people in the UK. The condition is generally age-related, with joint pain and stiffness developing as the cartilage between the bones gradually wears away.

OA changes and the inflammation involved causes difficulty moving and considerable pain. Rheumatoid arthritis (RA) tends to affect younger people and is caused by the body’s immune system attacking the joints. As a nation we tend to ignore our joints until they cause us problems, resulting in an increasing number of people taking long-term analgesics to control the pain or needing surgery to repair knees and hips.

Treatment guidelines followed by doctors in the UK recommend that people with arthritis are advised to maintain a healthy weight and keep physically active, while strengthening their muscles and protecting any damaged joints during daily activities.

Simple pain-killers are not without risk and the potential long-term side-effects of some of the most popular analgesics was recently highlighted by the UK’s National Institute for Health and Care Excellence (NICE).

While use of simple analgesics and non-steroidal anti-inflammatories (NSAIDs) can be reassuring and effective for those with muscular and joint pain, both groups of medicines may have side effects. For example, constipation and headache can occur with some analgesics, and indigestion and peptic ulceration with NSAIDs.

These side-effects can result in medicines not being taken correctly, limitation of dose or duration and, in some cases, lead to overt harm. Pharmacists can play a pivotal role in steering people with joint pain towards a prevention programme, promoting lifestyle and diet changes, including recommendation of clinically proven joint specific supplements.

In my experience, people often try these products as an alternative to, or to supplement, their prescription drugs. It’s important to be aware of the evidence, as the most popular may not be the most effective.

Omega-3 fatty acids

Omega-3 fatty acids have anti-inflammatory properties and are found in fish oils or formulated and sold as capsules or liquids. Studies assessing the benefits of fish oil, although quite old, have pro-vided reasonably good evidence that it is effective for some people with RA, providing pain relief, reducing the need for NSAIDs, and leading to symptom remission in some individuals.

It is important to bear in mind, however, that the benefits of fish oil supplementation in RA may not be apparent for up to three months – so perseverance is key. Very little evidence exists to suggest that fish oil supplements benefit people with OA.

Glucosamine & chondroitin

Glucosamine and chondroitin are popular joint health supplements that are available individually or in combination products. The clinical evidence supporting the use of glucosamine and chondroitin is mixed with only marginal benefits observed in clinical trials. GP’s have therefore been advised not to prescribe these supplements on the NHS; some people however do feel they see benefits.

Rosehip extracts

Roses and rosehip extracts have a long history of medicinal use and their potential benefits in the treatment of OA and RA have relatively recently come to light. The most consistent and robust re-search has been undertaken on extracts from a specific species of rosehip called Rosa canina, which has been found to contain a potent anti-inflammatory ingredient called galactolipid (or GOPO® for short).

GOPO® has been investigated in a number of well-designed studies conducted in Scandinavia and Germany involving people with either OA or RA. These studies found that GOPO® can rapidly reduce joint pain, stiffness and swelling, improve joint mobility and reduce the need for standard painkillers. In one combined analysis of all GOPO® studies, the researchers concluded that GOPO® may be more effective than either paracetamol or glu-cosamine in the treatment of OA.

In conclusion

Fish oils undoubtedly have many potential health benefits, however, a large number of standard capsules (around nine a day) are required to achieve a clinically-effective dose, which may be expensive and, ultimately, too heavy a treatment burden.

Glucosamine and chondroitin may benefit some individuals, however, it seems likely that the number of people who benefit will be matched by the number who don’t. GOPO® has been well studied and appears to have multiple benefits across a range of painful joint conditions, but beware of the ‘copy-cat’ products that may not necessarily contain the active ingredient.

Given the growing popularity of natural alternatives to conventional analgesics for joint pain, together with evidence to support their benefits, it would appear advisable for such options to be available via pharmacies. I would urge that customers look for evidence-based options and that if something is not working for them they should try something different with the advice of pharmacy staff.

(Dr Rod Hughes MD, FRCP is a consultant rheumatologist based in Surrey.)

More For You

The success story of Easter Pharmacy – the winner of Pharmacy Clinical Excellence Award 2024

Left to Right: Shailesh Solanki, Stephen Kinnock MP, Babatunde Sokoyo, Harry McQuillan, Chairman of Numark, Kalpesh Solanki and Rory BremnerEaster Pharmacy’s commandments for success

Easter Pharmacy’s commandments for success

Fostering a strong relationship between pharmacists and GPs can help resolve many issues in primary care, particularly regarding access to appointments and urgent care.

With this belief, Babatunde Sokoya, pharmacist superintendent at Easter Pharmacy, in Buckhurst Hill, Essex, aims to further strengthen collaboration with local practices and position his pharmacy as a leading example of integrated pharmacy service nationwide.

Keep ReadingShow less
Humanin Peptide: A Mitochondrial-Derived Factor with Potential Implications for Cellular Research

Humanin Peptide: A Mitochondrial-Derived Factor with Potential Implications for Cellular Research

Humanin is a mitochondrial-derived peptide (MDP) that has garnered interest due to its potential roles in cellular homeostasis, stress resistance, and metabolic regulation. Initially discovered in relation to neuroprotection, this small peptide has since been hypothesized to interact with multiple cellular pathways, suggesting its involvement in broader physiological processes. Given its origin from mitochondrial DNA (mtDNA), Humanin is believed to be a key player in mitochondrial communication with the nucleus and other cellular compartments, potentially impacting various research fields, including cellular aging, metabolic regulation, and cellular stress response.

Molecular Characteristics and Mechanisms

Keep ReadingShow less
The Realities of Dementia Care for Families

The Realities of Dementia Care for Families

Caring for a loved one with dementia is a journey that presents both emotional and practical challenges for families. Dementia, a progressive condition affecting memory, cognition, and behaviour, requires long-term care strategies and significant emotional resilience. Understanding the realities of dementia care can help families prepare and ensure their loved ones receive the best possible support.

1. The Emotional Toll on Families

Keep ReadingShow less
The UK Commission on Pharmacy Professional Leadership’s report outlined three potential pathways for the future of pharmacy leadership
UKPPLAB aims to enable greater collaboration across the pharmacy professional leadership bodies (gettyimages)

Exclusive: Pharmacy leaders have the opportunity to "co-create the future” with greater collaboration

By Sarwar Alam

Pharmacy leaders from across the sector need to work together in order to have a stronger voice in the future of the healthcare system, Sir Hugh Taylor, chair of the UK Pharmacy Professional Leadership Advisory Board (UKPPLAB), has told Pharmacy Business.

Keep ReadingShow less
Pharmacy First: Workforce capacity continues to be a concern
Community pharmacies in England delivered 2 million Pharmacy First consultations in the first year alone (gettyimages)

Pharmacy First needs proper support to reach its full potential: Numark

Sector needs a remuneration model that ensures pharmacies are not just delivering Pharmacy First service, but thriving while doing so 

Pharmacy First has demonstrated the enormous value of community pharmacy in providing accessible front-line care. However, pharmacists continue to face several challenges in delivering the service.

“Pharmacy First is a success, but it needs proper support to reach its full potential,” said Numark chairman Harry McQuillan.

Keep ReadingShow less